Select the option that best describes what you are looking for
Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.
Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.
Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.
Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.
Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.
Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.
Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.
Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.
Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.
Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.
Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.
Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.
Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.
Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.
Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.
Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.
Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.
Certified CRO services with NanoString GeoMx Digital Spatial Profiling.
De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.
Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.
Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.
Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.
Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.
Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.
Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.
Learn more about how our consulting services can help to support your journey to the clinic.
Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.
Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.
We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.
We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.
Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.
Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.
Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.
Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.
Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.
Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.
Patient-derived xenograft (PDX) models provide a predictive preclinical model for the evaluation of an agents efficacy prior to entering the clinic. The Crown Bioscience collection contains many sarcoma PDX models of both North American and Asian decent for a true representation of the variability found in the patient population. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER | CANCER TYPE | CANCER SUBTYPE | DESCRIPTION | # per page |
---|---|---|---|---|
SA0271 | Sarcoma | Spindle cell carcinoma | Alveolar soft part sarcoma. IHC results: CD99(+), CD(-), HMB45(+/-), PAS(+/-), CK(+/-), Des(-), NSE(+/-), S-100(-). | CLICK TO VIEW |
SA0319 | Sarcoma | Spindle cell carcinoma | Myxofibrosarcoma of abdominal wall. | CLICK TO VIEW |
SA0639 | Sarcoma | rhabdomyosarcoma | Pleomorphic rhabdomyosarcoma, IHC results: Myoglobin(+), Desmin(focus +), SMA(focus +), Myogenine(-), MyoD1(-), CD34(-), CD117(-), S-100(-), PMP-22(+/-, Ki-67(tumor cells 80% +). | CLICK TO VIEW |
SA0666 | Sarcoma | Spindle cell carcinoma | Fusocellular sarcoma. | CLICK TO VIEW |
SA10132 | Sarcoma | Sarcoma | Rhabdomyosarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. APPROXIMATELY 80% OF THE TISSUE INVOLVED BY TUMOR IN SECTIONS EXAMINED. 30% NECROSIS. TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10139 | Sarcoma | clear cell sarcoma | Recurrent Clear Cell Sarcoma. Pathol comment: ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10145 | Sarcoma | Sarcoma | Soft Tissue Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10146 | Sarcoma | NA | Soft Tissue Sarcoma. Pathol comment: ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10151 | Sarcoma | NA | Liposarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 70% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10153 | Sarcoma | Sarcoma | Synovial Sarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10154 | Sarcoma | Sarcoma | Soft Tissue Sarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10157 | Sarcoma | LEIOMYOSARCOMA | Mestastatic leiomyosarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10159 | Sarcoma | synovial sarcoma | Soft Tissue Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 70% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10160 | Sarcoma | LEIOMYOSARCOMA | Recurrent leiomyosarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10162 | Sarcoma | synovial sarcoma | NA | CLICK TO VIEW |
SA10164 | Sarcoma | Sarcoma | Leiomyosarcoma/Myxoid Sarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10166 | Sarcoma | Sarcoma | Leiomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10171 | Sarcoma | Soft Tissue Sarcoma | Soft Tissue Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 70% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10174 | Sarcoma | RHABDOMYOSARCOMA | Rhabdomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10175 | Sarcoma | Sarcoma | Soft Tissue Sarcoma. Mediastinal synovial sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10180 | Sarcoma | NA | Soft Tissue Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROX. 60% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. 20% NECROTIC. MALIGNANT CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10181 | Sarcoma | RHABDOMYOSARCOMA | Recurrent Rhabdomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED MALIGNANT TUMOR IN SECTIONS EXAMINED. 20% NECROTIC. MALIGNANT CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10182 | Sarcoma | LEIOMYOSARCOMA | Leiomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10192 | Sarcoma | Spindle cell carcinoma | N/A | CLICK TO VIEW |
SA10194 | Sarcoma | Sarcoma | Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 100% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA10196 | Sarcoma | NA | Sarcoma. Pathol comment: APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. C/W METASTATIC SARCOMA. APPROXIMATELY 5% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA10199 | Sarcoma | NA | Recurrent malignant solitary fibrous tumor. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 70% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA10202 | Sarcoma | Leiomyosarcoma | N/A | CLICK TO VIEW |
SA10215 | Sarcoma | NA | Sarcoma. | CLICK TO VIEW |
SA10216 | Sarcoma | Leiomyosarcoma | Leiomyosarcoma | CLICK TO VIEW |
SA10225 | Sarcoma | fibrosarcoma | Mestastatic pleomorphic high grade sarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10232 | Sarcoma | Ewing's sarcoma | Ewing's sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. FOCAL TUMOR NECROSIS. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10233 | Sarcoma | Ewing's sarcoma | Ewing's sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. 10% NECROSIS. APPROXIMATELY 90% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA10242 | Sarcoma | Sarcoma | Synovial Cell Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 80% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA10243 | Sarcoma | Malignant fibrous histiocytoma | Malignant fibrous histiocytoma. Undifferentiated pleomorphic sarcoma, high grade. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 80% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA10245 | Sarcoma | Sarcoma | Malignant fibrous histiocytoma. C/W RECURRENT/METASTATIC MALIGNANT FIBROUS HISTIOCYTOMA. C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 70% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA10992 | Sarcoma | NA | Desmoplastic Small Round Cell. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13127 | Sarcoma | Leiomyosarcoma | NA | CLICK TO VIEW |
SA13174 | Sarcoma | Liposarcoma | Soft Tissue Sarcoma. Liposarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY TUMOR IN SECTIONS EXAMINED. TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13179 | Sarcoma | Leiomyosarcoma | Soft Tissue Sarcoma. Recurrent leiomyosarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. APPROXIMATELY 70% OF TISSUE INVOLVED BY TUMOR IN SECTIONS EXAMINED. TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13187 | Sarcoma | NA | Sarcoma, malignant tumor most C/W rhabdoid tumor. Pathol comment: ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13230 | Sarcoma | Soft tissue sarcoma | NA | CLICK TO VIEW |
SA13256 | Sarcoma | NA | Retroperitoneal Sarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13284 | Sarcoma | NA | Soft Tissue Sarcoma. Metastatic intermediate grade sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 50% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13290 | Sarcoma | Soft Tissue Sarcoma | N/A | CLICK TO VIEW |
SA13298 | Sarcoma | Leiomyosarcoma | Leiomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13302 | Sarcoma | Soft Tissue Sarcoma | N/A | CLICK TO VIEW |
SA13305 | Sarcoma | Rhabdomyosarcoma | Soft Tissue Sarcoma. Rhabdomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13326 | Sarcoma | NA | Soft Tissue Sarcoma. Sarcoma, HG, with muxoid and chondroid features. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13327 | Sarcoma | fibrosarcoma | Soft Tissue Sarcoma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13354 | Sarcoma | Leiomyosarcoma | Soft Tissue Sarcoma. C/W PREVIOUS DIAGNOSED LEIOMYOSARCOMA. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 80% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13375 | Sarcoma | Sarcoma | Soft Tissue Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13389 | Sarcoma | Sarcoma | Soft Tissue Sarcoma. Epithelioid neoplasm, c/w myoepithelioma of soft tissues. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA1340 | Sarcoma | Leiomyosarcoma | NA | CLICK TO VIEW |
SA13404 | Sarcoma | Sarcoma | Soft Tissue Sarcoma. Synovial cell sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13405 | Sarcoma | NA | Soft Tissue Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13412 | Sarcoma | NA | Mestastatic mutifocal sarcoma, C/W synovial sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. 20% NECROTIC. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13441 | Sarcoma | synovial sarcoma | Spindle cell sarcoma, high grade. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 80% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA13452 | Sarcoma | NA | Myxoid sarcoma, most C/W myxoid leiomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 80% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA13455 | Sarcoma | NA | Leiomyosarcoma, high grade. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. 10% NECROSIS. APPROXIMATELY 80% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA13510 | Sarcoma | Gliosarcoma | NA | CLICK TO VIEW |
SA13542 | Sarcoma | Ewing's sarcoma | Ewing's Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 60% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA13543 | Sarcoma | Ewing's sarcoma | Ewing's sarcoma, small round blue cell tumor. Pathol comment: C/W RECURRENT EWING'S SARCOMAC/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA16043 | Sarcoma | NA | Soft Tissue Sarcoma. Pulmonary blastoma with rhabdomyosarcomatosis features. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA16044 | Sarcoma | NA | Soft Tissue Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA16047 | Sarcoma | NA | Soft Tissue Sarcoma, metastatic alveolar soft part sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 90% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA16050 | Sarcoma | Soft Tissue Sarcoma | Leiomyosarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 60% OF THE TISSUE INVOLVED MALIGNANT TUMOR IN SECTIONS EXAMINED. 20% NECROTIC. MALIGNANT CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA16052 | Sarcoma | NA | Sarcoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 60% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. | CLICK TO VIEW |
SA16055 | Sarcoma | Osteosarcoma | Osteosarcoma, recurrent osteosarcoma of the skull. Pathol comment: ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA16056 | Sarcoma | NA | Ewing's Sarcoma, extra osseus ewings. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 50% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
SA2398 | Sarcoma | N/A | N/A | CLICK TO VIEW |
SA2466 | Sarcoma | Rhabdomyosarcoma | NA | CLICK TO VIEW |
SA3224 | Sarcoma | NA | Malignant tumor, consider as metastatic sarcomatoid carcinoma or carcinosarcoma. | CLICK TO VIEW |
SA3283 | Sarcoma | NA | sarcoma | CLICK TO VIEW |
SA3296 | Sarcoma | NA | Right breast: Mesenchymal malignant tumor | CLICK TO VIEW |
SA3302 | Sarcoma | NA | Left thigh: pleomorphic sarcoma, high-grade, accord with dedifferentiated liposarcoma on the base of medical history. | CLICK TO VIEW |
SA3829 | Sarcoma | Ewing?s sarcoma | Pelvis: malignant tumor with massive necrosis and invaded bone, cartilage and skeletal muscle, consider Ewing's sarcoma based on medical history and IHC results. Vim+, CD99+, NSE+, CD57 sporadic +, Syn-, CHG-, S-100-, NF-. CK-. Ki67+70% | CLICK TO VIEW |
SA3831 | Sarcoma | osteosarcoma | Right thigh tumor: spindle cell sarcoma, consider fibrous cellular osteosarcoma on basis of medical history | CLICK TO VIEW |
SA3839 | Sarcoma | leiomysarcoma | Left pelvis: leiomysarcoma with high malignancy, infiltrating to fat and striated mscle tissues. | CLICK TO VIEW |
SA3840 | Sarcoma | osteosarcoma | Left proximal tibia: common type of osteosarcoma with chondroblastoma component infiltrating to soft tissue. | CLICK TO VIEW |
SA3841 | Sarcoma | NA | Puncture sample of scalp tumor: malignant tumor, consider metastatic osteosarcoma based on medical history and IHC results. IHC results: Vim(+), P53(-), S-100(-), CAM5.2(-), CD99(+), EMA(-), CK(-). | CLICK TO VIEW |
SA3847 | Sarcoma | Osteosarcoma | NA | CLICK TO VIEW |
SA3849 | Sarcoma | osteosarcoma | Right proximal humerus: common type of osteosarcoma after chemotherapy | CLICK TO VIEW |
SA3851 | Sarcoma | osteosarcoma | Right femur: common type of osteosarcoma | CLICK TO VIEW |
SA4008 | Sarcoma | osteosarcoma | Left humerus: osteosarcoma with giant cells component infiltrating to striated muscule. | CLICK TO VIEW |
SA4013 | Sarcoma | osteosarcoma | Lung: malignant sarcoma, consider metastatic osteosarcoma to lung on basis of medical history. | CLICK TO VIEW |
SA4028 | Sarcoma | NA | NA | CLICK TO VIEW |
SA4033 | Sarcoma | leiomyosarcoma | Right thigh: leiomyosarcoma with chondrosarcoma-like and osteosarcoma-like components (malignant mesenchymoma) | CLICK TO VIEW |
SA4040 | Sarcoma | NA | NA | CLICK TO VIEW |
SA4058 | Sarcoma | synovial sarcoma | Synovial sarcoma | CLICK TO VIEW |
SA4060 | Sarcoma | Osteosarcoma | N/A | CLICK TO VIEW |
SA4061 | Sarcoma | osteosarcoma | Left femur: high grade osteosarcoma, accord with postradiation osteosarcoma based on medical history. | CLICK TO VIEW |
SA4062 | Sarcoma | osteosarcoma | Osteosarcoma, metastases to lung (collected from lung) | CLICK TO VIEW |
SA4078 | Sarcoma | osteosarcoma | Left femur: convention osteosarcoma, infiltratiing to surrounding soft tissues. | CLICK TO VIEW |
SA4091 | Sarcoma | NA | Right fibula: spindle cell sarcoma with high grade component | CLICK TO VIEW |
SA4094 | Sarcoma | osteosarcoma | Lumbar vertebra: malignant carcinoma, consider small cell osteosarcoma with necrosis, infiltrating adjacent soft tissue. | CLICK TO VIEW |
SA4098 | Sarcoma | synovial sarcoma | Inferior lobe of right lung: sarcoma, consider metastatic synovial sarcoma based on medical histoty. | CLICK TO VIEW |
SA4109 | Sarcoma | chondrosarcoma | Left leg: accorded with chondrosarcoma based on morphology and IHC results. | CLICK TO VIEW |
SA4113 | Sarcoma | Chondrosarcoma | N/A | CLICK TO VIEW |
SA4138 | Sarcoma | Osteosarcoma | NA | CLICK TO VIEW |
SA4144 | Sarcoma | Sarcoma | NA | CLICK TO VIEW |
SA4148 | Sarcoma | Left pelvis: consider osteocarcinoma recurrence, based on medical history. | CLICK TO VIEW | |
SA4153 | Sarcoma | Spindle cell sarcoma | N/A | CLICK TO VIEW |
SA4196 | Sarcoma | synovial sarcoma | NA | CLICK TO VIEW |
SA4197 | Sarcoma | synovial sarcoma | NA | CLICK TO VIEW |
SA4227 | Sarcoma | Osteosarcoma | N/A | CLICK TO VIEW |
SA4235 | Sarcoma | Spindle cell sarcoma | N/A | CLICK TO VIEW |
SA5395 | Sarcoma | NA | NA for clinical diagnosis info. | CLICK TO VIEW |
SA5396 | Sarcoma | leiomyoma sarcoma | Uterine Leiomyoma sarcoma, Metastatic | CLICK TO VIEW |
Already Registered? Login
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy